Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,4056874,brain:body exposure ratio,The calculated pharmacokinetic advantage (brain:body exposure ratio) was between 21 and 55:1 when the combined treatment was used.,Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056874/),:,21 and 55,572,DB00262,Carmustine
,9918419,response rate,"Four complete and 11 partial responders were observed among 66 evaluable patients, yielding a response rate of 22.7% (95% confidence interval 12.9 32.5%).","Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918419/),%,22.7,1592,DB00262,Carmustine
,9918419,survival time,The median survival time was 6.4 months (range 0.1-52+ months).,"Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918419/),month,6.4,1593,DB00262,Carmustine
,26391155,t,"In NHL patients, cumulative higher trough concentrations over the eight administrations of the first cycle (TotC min, categorized by the median 58.71 mg/L) had significant prognostic value regarding the 5-year progression-free survival (PFS: 73.6 vs 46.5 %, P = 0.015) and 5-year overall survival (OS: 74.0 vs 52.2 %, P = 0.034).",Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391155/),[mg] / [l],58.71,5582,DB00262,Carmustine
,8269600,flow rate,O6-mG and the internal standard deoxyguanosine (dGuo) were eluted with a linear gradient of from 15% to 35% methanol in 0.5 M ammonium acetate (pH 6.5) at a flow rate of 1 ml/min.,Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[ml] / [min],1,18038,DB00262,Carmustine
,8269600,detection limit,The assay was linear over a 4-log concentration range with a detection limit of 0.1 microgram/ml.,Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[μg] / [ml],0.1,18039,DB00262,Carmustine
,8269600,terminal half-life (t1/2),"At 20 mg/kg i.v., plasma O6-mG gave a biexponential profile with a terminal half-life (t1/2) of 24 min and a total clearance (CLT) of 23.7 ml min-1 kg-1.",Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),min,24,18040,DB00262,Carmustine
,8269600,total clearance (CLT),"At 20 mg/kg i.v., plasma O6-mG gave a biexponential profile with a terminal half-life (t1/2) of 24 min and a total clearance (CLT) of 23.7 ml min-1 kg-1.",Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[ml] / [kg·min],23.7,18041,DB00262,Carmustine
,9815739,plasma half-life (t1/2),"Mean plasma half-life (t1/2) in the 4-h infusion group was 197 min, and the volume of distribution approximated plasma volume.",Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815739/),min,197,26548,DB00262,Carmustine
,12525514,oral bioavailability,The oral bioavailability of SarCNU was 80% +/- 37%.,"SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525514/),%,80,28099,DB00262,Carmustine
,12525514,terminal phase half-life,The terminal phase half-life was similar after intravenous (58.4 +/- 23.5 minutes) or oral (64.0 +/- 34.8 minutes) administration.,"SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525514/),min,58.4,28100,DB00262,Carmustine
,12525514,terminal phase half-life,The terminal phase half-life was similar after intravenous (58.4 +/- 23.5 minutes) or oral (64.0 +/- 34.8 minutes) administration.,"SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525514/),min,64.0,28101,DB00262,Carmustine
,12525514,total plasma clearance,"The total plasma clearance was 20.4 +/- 8.8 L/h/m2, and the apparent volume of distribution was 29.9 +/- 17.6 L/m2.","SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525514/),[l] / [h·m2],20.4,28102,DB00262,Carmustine
,12525514,apparent volume of distribution,"The total plasma clearance was 20.4 +/- 8.8 L/h/m2, and the apparent volume of distribution was 29.9 +/- 17.6 L/m2.","SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525514/),[l] / [m2],29.9,28103,DB00262,Carmustine
,12525514,MTD,"SarCNU was well tolerated and the MTD was 1,075 mg/m2.","SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525514/),[mg] / [m2],"1,075",28104,DB00262,Carmustine
,8630682,steady-state concentrations,"At doses above 37.5 g/m2/day, steady-state concentrations of dThd approached or exceeded 1 mM, a concentration that nearly completely abolished BCNU-induced PADPRP activity in preclinical studies.",A phase I pilot study of BCNU plus thymidine in patients with refractory cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630682/),mM,1,29471,DB00262,Carmustine
,3229131,peak concentration,"BCNU is soluble in SO (peak concentration in micrograms/ml 1020, 750, and 294 at 37 degrees C, 21 degrees C, and 4 degrees C, respectively), and stable (half-life = 6.7 weeks at 37 degrees C, 17.9 weeks at 21 degrees C).","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),[μg] / [ml],1020,38624,DB00262,Carmustine
,3229131,peak concentration,"BCNU is soluble in SO (peak concentration in micrograms/ml 1020, 750, and 294 at 37 degrees C, 21 degrees C, and 4 degrees C, respectively), and stable (half-life = 6.7 weeks at 37 degrees C, 17.9 weeks at 21 degrees C).","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),[μg] / [ml],750,38625,DB00262,Carmustine
,3229131,peak concentration,"BCNU is soluble in SO (peak concentration in micrograms/ml 1020, 750, and 294 at 37 degrees C, 21 degrees C, and 4 degrees C, respectively), and stable (half-life = 6.7 weeks at 37 degrees C, 17.9 weeks at 21 degrees C).","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),[μg] / [ml],294,38626,DB00262,Carmustine
,3229131,half-life,"BCNU is soluble in SO (peak concentration in micrograms/ml 1020, 750, and 294 at 37 degrees C, 21 degrees C, and 4 degrees C, respectively), and stable (half-life = 6.7 weeks at 37 degrees C, 17.9 weeks at 21 degrees C).","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),weeks,6.7,38627,DB00262,Carmustine
,3229131,half-life,"BCNU is soluble in SO (peak concentration in micrograms/ml 1020, 750, and 294 at 37 degrees C, 21 degrees C, and 4 degrees C, respectively), and stable (half-life = 6.7 weeks at 37 degrees C, 17.9 weeks at 21 degrees C).","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),weeks,17.9,38628,DB00262,Carmustine
,3229131,partition coefficient,BCNU is released from SO to water (partition coefficient = 10.28 +/- 2.16).,"BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),,10.28,38629,DB00262,Carmustine
,3229131,inhibitory doses (ID50),"Its median inhibitory doses (ID50) on bovine retinal pigment epithelial (RPE), rabbit RPE, and subconjunctival fibroblast cells are 13, 1.9, and 15.6 micrograms/ml, respectively.","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),[μg] / [ml],13,38630,DB00262,Carmustine
,3229131,inhibitory doses (ID50),"Its median inhibitory doses (ID50) on bovine retinal pigment epithelial (RPE), rabbit RPE, and subconjunctival fibroblast cells are 13, 1.9, and 15.6 micrograms/ml, respectively.","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),[μg] / [ml],1.9,38631,DB00262,Carmustine
,3229131,inhibitory doses (ID50),"Its median inhibitory doses (ID50) on bovine retinal pigment epithelial (RPE), rabbit RPE, and subconjunctival fibroblast cells are 13, 1.9, and 15.6 micrograms/ml, respectively.","BCNU in silicone oil in proliferative vitreoretinopathy: I. Solubility, stability (in vitro and in vivo), and antiproliferative (in vitro) studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229131/),[μg] / [ml],15.6,38632,DB00262,Carmustine
,2058178,limit of detection,"The optimized polarographic determination, previously applied to BCNU and CCNU, attained a limit of detection of 0.3 micrograms fotemustine/ml plasma and 1 microgram/g in other tissues; the calibration curve in electrolyte or in plasma was linear between 0.5 and 100 micrograms/ml.",Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058178/),,0,42060,DB00262,Carmustine
,2058178,Recovery,Recovery of fotemustine was 76-90% from lung greater than kidney greater than plasma greater than brain greater than liver; the variability coefficients were low (4.0-7.3%).,Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058178/),%,76-90,42061,DB00262,Carmustine
,24874252,overall survival (OS),"The median overall survival (OS) was 322 days (95% CI, 173-471 days).",Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874252/),d,322,46795,DB00262,Carmustine
,8270970,Duration of neutropenia,Duration of neutropenia was longer for patients treated with 90 mg/m2 (31.7 days) than for patients treated with doses up to 75 mg/m2 (22.1 days) (P < .05).,"Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270970/),d,31.7,47385,DB00262,Carmustine
,8270970,Duration of neutropenia,Duration of neutropenia was longer for patients treated with 90 mg/m2 (31.7 days) than for patients treated with doses up to 75 mg/m2 (22.1 days) (P < .05).,"Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270970/),d,22.1,47386,DB00262,Carmustine
,16087946,survival,Median survival for these patients was 1.3 years compared with 2.7 years for those without the variant (P = .043).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,1.3,79014,DB00262,Carmustine
,16087946,survival,Median survival for these patients was 1.3 years compared with 2.7 years for those without the variant (P = .043).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,2.7,79015,DB00262,Carmustine
,16087946,survival,Median survival for patients with deletions of glutathione-S-transferase M1 gene was 3.5 v 1.5 years for patients with one or both copies (P = .041).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,3,79016,DB00262,Carmustine
,16087946,survival,Median survival for patients with deletions of glutathione-S-transferase M1 gene was 3.5 v 1.5 years for patients with one or both copies (P = .041).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,1.5,79017,DB00262,Carmustine
,24739422,overall,"In patients with newly diagnosed MGs, the overall survival rates at 12 months and 24 months were 100.0% and 68.8%, and the progression-free survival rate at 12 months was 62.5%.",A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739422/),%,100,94823,DB00262,Carmustine
,24739422,overall,"In patients with newly diagnosed MGs, the overall survival rates at 12 months and 24 months were 100.0% and 68.8%, and the progression-free survival rate at 12 months was 62.5%.",A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739422/),%,68.8,94824,DB00262,Carmustine
,24739422,progression-free survival rate,"In patients with newly diagnosed MGs, the overall survival rates at 12 months and 24 months were 100.0% and 68.8%, and the progression-free survival rate at 12 months was 62.5%.",A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739422/),%,62.5,94825,DB00262,Carmustine
,24739422,progression-free survival rate,"In patients with recurrent MGs, the progression-free survival rate at 6 months was 37.5%.",A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739422/),%,37.5,94826,DB00262,Carmustine
exceeded,8468721,area under the curve (AUC),"Twelve (60%) of the 20 had values for area under the curve (AUC) for BCNU concentration x time that exceeded 600 (micrograms/mL) x minute, whereas only two (11%) of the 18 without pulmonary injury had values above this level (P < .03).","Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8468721/),[μgrams] / [min·ml)],600,104968,DB00262,Carmustine
greater,8468721,AUC,"Thus, 12 (86%) of 14 patients with BCNU AUC greater than 600 (micrograms/mL) x minute developed lung injury.","Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8468721/),[μgrams] / [min·ml)],600,104969,DB00262,Carmustine
,1612960,Enhancement ratios,"Enhancement ratios of about 2.4 and 4.7 were observed with BCNU and CY, respectively.",Enhancement of misonidazole chemosensitization effect by mild local hyperthermia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1612960/),,2.4,118022,DB00262,Carmustine
,1612960,Enhancement ratios,"Enhancement ratios of about 2.4 and 4.7 were observed with BCNU and CY, respectively.",Enhancement of misonidazole chemosensitization effect by mild local hyperthermia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1612960/),,4.7,118023,DB00262,Carmustine
,6722774,half-life,Pharmacokinetic studies of diaziquone in the plasma of athymic mice indicated rapid clearance with a half-life of approximately 11.5 min.,Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6722774/),min,11.5,119287,DB00262,Carmustine
,2305718,Peak plasma melphalan concentrations,Peak plasma melphalan concentrations in the three patients ranged from 0.354 (patient 2) to 1.768 micrograms/ml (patient 1).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[μg] / [ml],0.354,119352,DB00262,Carmustine
,2305718,Peak plasma melphalan concentrations,Peak plasma melphalan concentrations in the three patients ranged from 0.354 (patient 2) to 1.768 micrograms/ml (patient 1).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[μg] / [ml],1.768,119353,DB00262,Carmustine
,2305718,concentration X time products (C x Ts),"Plasma melphalan concentration X time products (C x Ts) showed extreme variability in one patient (patient 2), ranging from 0.76 to 4.48 micrograms.h/ml.",Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[h·μg] / [ml],0.76 to 4.48,119354,DB00262,Carmustine
,2305718,plasma C X T ratios,The p.o.:i.v. plasma C X T ratios for high-dose melphalan ranged between 0.09 (patient 3) and 0.58 (patient 2).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),,0.09,119355,DB00262,Carmustine
,2305718,plasma C X T ratios,The p.o.:i.v. plasma C X T ratios for high-dose melphalan ranged between 0.09 (patient 3) and 0.58 (patient 2).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),,0.58,119356,DB00262,Carmustine
less,3948304,elimination half-life (t1/2,The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration.,Pharmacokinetics of high-dose melphalan in children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948304/),min,80,121683,DB00262,Carmustine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"76,600",127603,DB00262,Carmustine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"90,600",127604,DB00262,Carmustine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],525,127605,DB00262,Carmustine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],648,127606,DB00262,Carmustine
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,544,127607,DB00262,Carmustine
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,677,127608,DB00262,Carmustine
,9869217,time to progression,Median time to progression and survival were 13 and 14 months respectively.,"Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),month,13,128008,DB00262,Carmustine
,9869217,survival,Median time to progression and survival were 13 and 14 months respectively.,"Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),month,14,128009,DB00262,Carmustine
,9869217,plasma concentrations,"The mean +/- SD 2 hr and 6 hr plasma concentrations were 0.92 +/- 0.43 microg/ml and 0.36 +/- 0.12 microg/ml, respectively.","Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),[μg] / [ml],0.92,128010,DB00262,Carmustine
,9869217,plasma concentrations,"The mean +/- SD 2 hr and 6 hr plasma concentrations were 0.92 +/- 0.43 microg/ml and 0.36 +/- 0.12 microg/ml, respectively.","Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),[μg] / [ml],0.36,128011,DB00262,Carmustine
,22619524,drug-loading capacity,"The optimum drug immobilization condition was by reacting 0.5 mg PAA-GO with 0.4 mg BCNU, and the drug-loading capacity and residual drug activity were 198 μg BCNU/mg PAA-GO and 70%, respectively.",Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22619524/),μg,198,130355,DB00262,Carmustine
,22619524,residual drug activity,"The optimum drug immobilization condition was by reacting 0.5 mg PAA-GO with 0.4 mg BCNU, and the drug-loading capacity and residual drug activity were 198 μg BCNU/mg PAA-GO and 70%, respectively.",Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22619524/),%,70,130356,DB00262,Carmustine
,22619524,half-life,This nanocarrier significantly prolonged the half-life of bound BCNU from 19 to 43 hours compared with free drug and showed efficient intracellular uptake by GL261 cancer cells.,Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22619524/),h,19 to 43,130357,DB00262,Carmustine
,9829757,peak O6BG CSF concentration,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),μM,412,131145,DB00262,Carmustine
,9829757,t1/2,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h,0.52,131146,DB00262,Carmustine
,9829757,clearance,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),[ml] / [min],0.22,131147,DB00262,Carmustine
,9829757,area under the concentration-time curve,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h·μM,319,131148,DB00262,Carmustine
,9829757,peak CSF concentration,"The peak CSF concentration of 8-oxo-O6BG in CSF was 1.9+/-0.4 microM, the t1/2 was 0.76+/-0.03 h, and the area under the concentration-time curve was 5.0+/-1.1 microM x h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),μM,1.9,131149,DB00262,Carmustine
,9829757,t1/2,"The peak CSF concentration of 8-oxo-O6BG in CSF was 1.9+/-0.4 microM, the t1/2 was 0.76+/-0.03 h, and the area under the concentration-time curve was 5.0+/-1.1 microM x h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h,0.76,131150,DB00262,Carmustine
,9829757,area under the concentration-time curve,"The peak CSF concentration of 8-oxo-O6BG in CSF was 1.9+/-0.4 microM, the t1/2 was 0.76+/-0.03 h, and the area under the concentration-time curve was 5.0+/-1.1 microM x h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h·μM,5.0,131151,DB00262,Carmustine
,9829757,plasma peak concentration,"The plasma peak concentration of O6BG was 0.4 microM at 30 min, and the concentration was <0.1 microM by 3 h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),μM,0.4,131152,DB00262,Carmustine
,3719578,elimination constant,"Average pharmacokinetic parameters for bioavailable plasma BCNU, calculated on the basis of a one-compartment model, include an elimination constant of 0.031 min-1 and a volume of distribution of 5.1 L/kg.",Pharmacokinetics and immediate effects of high-dose carmustine in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719578/),1/[min],0.031,138296,DB00262,Carmustine
,3719578,volume of distribution,"Average pharmacokinetic parameters for bioavailable plasma BCNU, calculated on the basis of a one-compartment model, include an elimination constant of 0.031 min-1 and a volume of distribution of 5.1 L/kg.",Pharmacokinetics and immediate effects of high-dose carmustine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719578/),[l] / [kg],5.1,138297,DB00262,Carmustine
,3719578,clearance,Average clearance of total plasma BCNU is 77.6 ml/kg/min.,Pharmacokinetics and immediate effects of high-dose carmustine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719578/),[ml] / [kg·min],77.6,138298,DB00262,Carmustine
,3719578,peak concentration,"When corrected to a constant dose of 1 g/m2, the average peak concentration at the end of the infusion was 7.8 microM and the area under the curve was 538 microM X min.",Pharmacokinetics and immediate effects of high-dose carmustine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719578/),μM,7.8,138299,DB00262,Carmustine
,3719578,area under the curve,"When corrected to a constant dose of 1 g/m2, the average peak concentration at the end of the infusion was 7.8 microM and the area under the curve was 538 microM X min.",Pharmacokinetics and immediate effects of high-dose carmustine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719578/),min·μM,538,138300,DB00262,Carmustine
,2140824,peak plasma concentration,"When 50 mg/kg of CCNU was given i.p., the peak plasma concentration of CCNU was about 3 micrograms/ml.",Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),[μg] / [ml],3,143272,DB00262,Carmustine
,2140824,terminal half-time (T1/2),CCNU was eliminated with biphasic kinetics that had a terminal half-time (T1/2) of approximately 47 min.,Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),min,47,143273,DB00262,Carmustine
,2140824,initial,"SR-2508 was eliminated from the plasma with biphasic kinetics having an initial and terminal T1/2 of approximately 11 and approximately 76 min, respectively.",Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),min,11,143274,DB00262,Carmustine
,2140824,terminal T1/2,"SR-2508 was eliminated from the plasma with biphasic kinetics having an initial and terminal T1/2 of approximately 11 and approximately 76 min, respectively.",Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),min,76,143275,DB00262,Carmustine
,2140824,peak tumor concentration,SR-2508 reached a peak tumor concentration of about 500 micrograms/ml in 30 min.,Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),[μg] / [ml],500,143276,DB00262,Carmustine
,2140824,elimination T1/2,"The elimination T1/2 for SR-2508 in unclamped and clamped tumors was approximately 81 and approximately 42 min, respectively.",Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),min,81,143277,DB00262,Carmustine
,2140824,elimination T1/2,"The elimination T1/2 for SR-2508 in unclamped and clamped tumors was approximately 81 and approximately 42 min, respectively.",Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),min,42,143278,DB00262,Carmustine
less,2140824,surviving fractions,MISO significantly potentiated the cytotoxicity of BCNU in clamped tumors at surviving fractions less than or equal to 0.5.,Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),,0.5,143279,DB00262,Carmustine
,2140824,surviving fraction,MISO did not potentiate the cytotoxicity of CCNU until the surviving fraction reached 0.05.,Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140824/),,0.05,143280,DB00262,Carmustine
,24292607,overall,"In patients with newly diagnosed MGs, the overall survival rates at 12 months and 24 months were 100.0% and 68.8%, and the progression-free survival rate at 12 months was 62.5%.",A Multicenter Phase I/II Study of the BCNU Implant (Gliadel® Wafer) for Japanese Patients with Malignant Gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24292607/),%,100,144555,DB00262,Carmustine
,24292607,overall,"In patients with newly diagnosed MGs, the overall survival rates at 12 months and 24 months were 100.0% and 68.8%, and the progression-free survival rate at 12 months was 62.5%.",A Multicenter Phase I/II Study of the BCNU Implant (Gliadel® Wafer) for Japanese Patients with Malignant Gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24292607/),%,68.8,144556,DB00262,Carmustine
,24292607,progression-free survival rate,"In patients with newly diagnosed MGs, the overall survival rates at 12 months and 24 months were 100.0% and 68.8%, and the progression-free survival rate at 12 months was 62.5%.",A Multicenter Phase I/II Study of the BCNU Implant (Gliadel® Wafer) for Japanese Patients with Malignant Gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24292607/),%,62.5,144557,DB00262,Carmustine
,24292607,progression-free survival rate,"In patients with recurrent MGs, the progression-free survival rate at 6 months was 37.5%.",A Multicenter Phase I/II Study of the BCNU Implant (Gliadel® Wafer) for Japanese Patients with Malignant Gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24292607/),%,37.5,144558,DB00262,Carmustine
,8402672,total body clearance,The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m2: total body clearance (19.3 +/- 6.2 liter/h/m2) and volume of distribution at steady state (486 +/- 254 liter/m2) were not altered by increasing the dose.,Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),[l] / [h·m2],19.3,155501,DB00262,Carmustine
,8402672,volume of distribution at steady state,The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m2: total body clearance (19.3 +/- 6.2 liter/h/m2) and volume of distribution at steady state (486 +/- 254 liter/m2) were not altered by increasing the dose.,Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),[l] / [m2],486,155502,DB00262,Carmustine
,8402672,area under the concentration +/- time curve ratio,"Whereas cellular versus plasma maximum concentration ratio was near 1, the area under the concentration +/- time curve ratio reached 100, suggesting a long elimination half-life from cells.",Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),,100,155503,DB00262,Carmustine
,12953345,t1/2 alpha,"O6-Benzylguanine is eliminated rapidly from the plasma compartment in humans (t1/2 alpha and t1/2 beta are 2 +/- 2 min and 26 +/- 15 min [mean +/- SD, n = 7], respectively), and its plasma clearance (513 +/- 148 mL/min/m2) is not dose dependent.","Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953345/),min,2,156147,DB00262,Carmustine
,12953345,t1/2 beta,"O6-Benzylguanine is eliminated rapidly from the plasma compartment in humans (t1/2 alpha and t1/2 beta are 2 +/- 2 min and 26 +/- 15 min [mean +/- SD, n = 7], respectively), and its plasma clearance (513 +/- 148 mL/min/m2) is not dose dependent.","Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953345/),min,26,156148,DB00262,Carmustine
,12953345,plasma clearance,"O6-Benzylguanine is eliminated rapidly from the plasma compartment in humans (t1/2 alpha and t1/2 beta are 2 +/- 2 min and 26 +/- 15 min [mean +/- SD, n = 7], respectively), and its plasma clearance (513 +/- 148 mL/min/m2) is not dose dependent.","Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953345/),[ml] / [m2·min],513,156149,DB00262,Carmustine
,1617631,peak plasma concentration,"Pharmacokinetic studies indicated a rapid clearance of L-histidinol following a bolus dose (250 mg/kg i.p.), peak plasma concentration of 200 micrograms/ml (1.4 mM), and beta phase t1/2 of 12.6 min.",L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),[μg] / [ml],200,168290,DB00262,Carmustine
,1617631,beta phase t1/2,"Pharmacokinetic studies indicated a rapid clearance of L-histidinol following a bolus dose (250 mg/kg i.p.), peak plasma concentration of 200 micrograms/ml (1.4 mM), and beta phase t1/2 of 12.6 min.",L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),min,12.6,168291,DB00262,Carmustine
no greater,1617631,Maximum tolerable plasma steady state concentrations,Maximum tolerable plasma steady state concentrations with a 24-h infusion (2000 mg/kg/24 h) were no greater than 25 micrograms/ml (0.18 mM).,L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),[μg] / [ml],25,168292,DB00262,Carmustine
,1617631,Maximum tolerable plasma steady state concentrations,Maximum tolerable plasma steady state concentrations with a 24-h infusion (2000 mg/kg/24 h) were no greater than 25 micrograms/ml (0.18 mM).,L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),mM,0.18,168293,DB00262,Carmustine
,2745188,peak plasma concentration,"When 12 mg/kg of BCNU was given i.p. without MISO, the peak plasma concentration was about 6 micrograms/ml, and the elimination half-time was about 16 min.","Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2745188/),[μg] / [ml],6,171763,DB00262,Carmustine
,2745188,elimination half-time,"When 12 mg/kg of BCNU was given i.p. without MISO, the peak plasma concentration was about 6 micrograms/ml, and the elimination half-time was about 16 min.","Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2745188/),min,16,171764,DB00262,Carmustine
,2745188,elimination half-time,The elimination half-time of MISO from the plasma (approximately 142 min) was identical for rats with unclamped or clamped tumors.,"Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2745188/),min,142,171765,DB00262,Carmustine
,2745188,half-time,The half-time for the disappearance of MISO from unclamped tumors was about 98 min.,"Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2745188/),min,98,171766,DB00262,Carmustine
,2745188,half-time,MISO disappeared in the clamped tumors with a half-time of about 40 min.,"Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2745188/),min,40,171767,DB00262,Carmustine
,11592341,half-life,"During the initial 90 min after i.v. injection to mice, SarCNU was eliminated from plasma in a monoexponential manner with a mean half-life of 9.8 +/- 0.8 min.",Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),min,9.8,176427,DB00262,Carmustine
,11592341,total plasma clearance,The total plasma clearance was 47.3 +/- 8.7 ml/min per kg and the apparent volume of distribution was 0.7 +/- 0.1 l/kg.,Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[ml] / [kg·min],47.3,176428,DB00262,Carmustine
,11592341,apparent volume of distribution,The total plasma clearance was 47.3 +/- 8.7 ml/min per kg and the apparent volume of distribution was 0.7 +/- 0.1 l/kg.,Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[l] / [kg],0.7,176429,DB00262,Carmustine
,11592341,Peak plasma levels,"Peak plasma levels provided by a dose of 100 mg/kg given by the i.v. and oral routes were 142.4 microg/ml (0.5 min) and 27.8 microg/ml (9.8 min), respectively.",Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[μg] / [ml],142.4,176430,DB00262,Carmustine
,11592341,Peak plasma levels,"Peak plasma levels provided by a dose of 100 mg/kg given by the i.v. and oral routes were 142.4 microg/ml (0.5 min) and 27.8 microg/ml (9.8 min), respectively.",Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[μg] / [ml],27.8,176431,DB00262,Carmustine
,11592341,oral bioavailability,The mean oral bioavailability of the drug was 57.3 +/- 12.6% in mice.,Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),%,57.3,176432,DB00262,Carmustine
,11592341,half-lives,"In comparison, the disposition of SarCNU in dogs after rapid i.v. injection was biexponential, with half-lives of 5.4 +/- 8.4 min and 40.8 +/- 9.0 min for the initial and terminal disposition phases, respectively.",Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),min,5.4,176433,DB00262,Carmustine
,11592341,half-lives,"In comparison, the disposition of SarCNU in dogs after rapid i.v. injection was biexponential, with half-lives of 5.4 +/- 8.4 min and 40.8 +/- 9.0 min for the initial and terminal disposition phases, respectively.",Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),min,40.8,176434,DB00262,Carmustine
,11592341,total plasma clearance,"Mean values of the total plasma clearance and apparent volume of distribution were 17.8 +/- 1.8 ml/min per kg and 1.1 +/- 0.3 l/kg, respectively.",Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[ml] / [kg·min],17.8,176435,DB00262,Carmustine
,11592341,apparent volume of distribution,"Mean values of the total plasma clearance and apparent volume of distribution were 17.8 +/- 1.8 ml/min per kg and 1.1 +/- 0.3 l/kg, respectively.",Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[l] / [kg],1.1,176436,DB00262,Carmustine
,11592341,Cmax,The Cmax was 18.5 +/- 6.5 microg/ml after i.v. injection and 8.5 0.4 microg/ml after oral administration of a 10 mg/kg dose.,Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[μg] / [ml],18.5,176437,DB00262,Carmustine
,11592341,Cmax,The Cmax was 18.5 +/- 6.5 microg/ml after i.v. injection and 8.5 0.4 microg/ml after oral administration of a 10 mg/kg dose.,Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[μg] / [ml],8.5,176438,DB00262,Carmustine
,11592341,Cmax,The Cmax was 18.5 +/- 6.5 microg/ml after i.v. injection and 8.5 0.4 microg/ml after oral administration of a 10 mg/kg dose.,Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),[μg] / [ml],0.4,176439,DB00262,Carmustine
,11592341,Oral bioavailability,Oral bioavailability of the drug in dogs (71.7 +/- 21.2%) was greater than that observed in mice.,Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592341/),%,71.7,176440,DB00262,Carmustine
,11032594,elimination half-life,"O(6)-BG rapidly disappeared from plasma (elimination half-life = 0. 54 +/- 0.14 hours) and was converted to a longer-lived metabolite, 8-oxo-O(6)-BG (elimination half-life = 5.6 +/- 2.7 hours) and further to 8-oxoguanine.",Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11032594/),h,0. 54,185470,DB00262,Carmustine
,11032594,elimination half-life,"O(6)-BG rapidly disappeared from plasma (elimination half-life = 0. 54 +/- 0.14 hours) and was converted to a longer-lived metabolite, 8-oxo-O(6)-BG (elimination half-life = 5.6 +/- 2.7 hours) and further to 8-oxoguanine.",Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11032594/),h,5.6,185471,DB00262,Carmustine
,688274,half-time,The disappearance of BCNU in vitro was found to be first-order with a half-time of 11.6 minutes (+/- 0.5 SD) in volunteers and 15.6 minutes (+/- 2.3 SD) in patients.,Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688274/),min,11.6,185755,DB00262,Carmustine
,688274,half-time,The disappearance of BCNU in vitro was found to be first-order with a half-time of 11.6 minutes (+/- 0.5 SD) in volunteers and 15.6 minutes (+/- 2.3 SD) in patients.,Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688274/),min,15.6,185756,DB00262,Carmustine
,688274,volume of distribution,"Analysis of the pharmacokinetics of BCNU in 20 patients using a two-compartment open model demonstrated a volume of distribution of 3.25 liters/kg (+/- 1.69 SD), a clearance of 56 ml/minute/kg (+/- 56 SD), and a transfer constant from the central compartment to the outside (K10) OF 0.0324 MINUTE-1 (+/- 41% SD), which was close to the decomposition rate observed for BCNU in serum in vitro.",Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688274/),[l] / [kg],3.25,185757,DB00262,Carmustine
,688274,clearance,"Analysis of the pharmacokinetics of BCNU in 20 patients using a two-compartment open model demonstrated a volume of distribution of 3.25 liters/kg (+/- 1.69 SD), a clearance of 56 ml/minute/kg (+/- 56 SD), and a transfer constant from the central compartment to the outside (K10) OF 0.0324 MINUTE-1 (+/- 41% SD), which was close to the decomposition rate observed for BCNU in serum in vitro.",Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688274/),[ml] / [kg·min],56,185758,DB00262,Carmustine
,688274,transfer constant from the central compartment to the outside (K10),"Analysis of the pharmacokinetics of BCNU in 20 patients using a two-compartment open model demonstrated a volume of distribution of 3.25 liters/kg (+/- 1.69 SD), a clearance of 56 ml/minute/kg (+/- 56 SD), and a transfer constant from the central compartment to the outside (K10) OF 0.0324 MINUTE-1 (+/- 41% SD), which was close to the decomposition rate observed for BCNU in serum in vitro.",Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/688274/),1/[Minute],0.0324,185759,DB00262,Carmustine
,2954633,half-life,"In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40.76 h and its in vivo terminal half-life of 0.52 h.",Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954633/),h,40.76,186414,DB00262,Carmustine
,2954633,terminal half-life,"In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40.76 h and its in vivo terminal half-life of 0.52 h.",Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954633/),h,0.52,186415,DB00262,Carmustine
,2983894,Brain-to-systemic exposure ratios,"Brain-to-systemic exposure ratios ranged from 18:1 to 87:1, depending on the pump flow rate and method of calculation.",Arterial drug infusion with extracorporeal removal. Internal carotid carmustine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2983894/),,18:1,188652,DB00262,Carmustine
,2983894,Brain-to-systemic exposure ratios,"Brain-to-systemic exposure ratios ranged from 18:1 to 87:1, depending on the pump flow rate and method of calculation.",Arterial drug infusion with extracorporeal removal. Internal carotid carmustine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2983894/),,87:1,188653,DB00262,Carmustine
,7248980,half-life,The half-life of BCNU added to plasma in vitro was 1413 mins at 0 degrees C and 12 mins at 37 degrees C during incubation.,Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248980/),min,1413,193912,DB00262,Carmustine
,7248980,half-life,The half-life of BCNU added to plasma in vitro was 1413 mins at 0 degrees C and 12 mins at 37 degrees C during incubation.,Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248980/),min,12,193913,DB00262,Carmustine
,7248980,half-life,BCNU kinetics in blood of treated patients was calculated using the two-compartment open model; the half-life of the drug was 1.4 mins in the first phase and 17.8 mins in the second.,Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248980/),min,1.4,193914,DB00262,Carmustine
,7248980,half-life,BCNU kinetics in blood of treated patients was calculated using the two-compartment open model; the half-life of the drug was 1.4 mins in the first phase and 17.8 mins in the second.,Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248980/),min,17.8,193915,DB00262,Carmustine
,7248980,distribution volume,Mean distribution volume was 2.59 liters/kg and plasma clearance was 16.7 ml/min/kg.,Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248980/),[l] / [kg],2.59,193916,DB00262,Carmustine
,7248980,plasma clearance,Mean distribution volume was 2.59 liters/kg and plasma clearance was 16.7 ml/min/kg.,Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248980/),[ml] / [kg·min],16.7,193917,DB00262,Carmustine
,1537079,t1/2 beta,"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),min,256,199424,DB00262,Carmustine
,1537079,mean residence time (MRT),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),min,346,199425,DB00262,Carmustine
,1537079,AUC,"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[min·μg] / [ml],"4,972",199426,DB00262,Carmustine
,1537079,volume of distribution at steady state (Vdss),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[l] / [m2],6.6,199427,DB00262,Carmustine
,1537079,clearance (CL),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[ml] / [(m)^2·min],20.4,199428,DB00262,Carmustine
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB00262,Carmustine
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB00262,Carmustine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],80,211163,DB00262,Carmustine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],100,211164,DB00262,Carmustine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],150,211165,DB00262,Carmustine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],110,211166,DB00262,Carmustine
,15534084,overall survival,"At median follow-up of 34 (13-58) months, all HRPBC patients remain alive and free of disease; the MBC group has event-free survival and overall survival rates of 45 and 70%, respectively.",Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15534084/),,70,252895,DB00262,Carmustine
,11302252,half-life,The half-life of temozolomide was 1.86 (+/-0.31) h.,"A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302252/),h,1.86,255049,DB00262,Carmustine
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],73.6,256672,DB00262,Carmustine
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],88.3,256673,DB00262,Carmustine
,3247301,alpha,"The plasma concentration-time curves were fit to a two-compartment model with a mean (SE) alpha, beta, and total-body clearance of 2.898 (0.913) hr-1, 0.1228 (0.0179) hr-1, and 7.211 (2.862) liters/hr.kg, respectively.","Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247301/),1/[h],2.898,261515,DB00262,Carmustine
,3247301,beta,"The plasma concentration-time curves were fit to a two-compartment model with a mean (SE) alpha, beta, and total-body clearance of 2.898 (0.913) hr-1, 0.1228 (0.0179) hr-1, and 7.211 (2.862) liters/hr.kg, respectively.","Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247301/),1/[h],0.1228,261516,DB00262,Carmustine
,3247301,total-body clearance,"The plasma concentration-time curves were fit to a two-compartment model with a mean (SE) alpha, beta, and total-body clearance of 2.898 (0.913) hr-1, 0.1228 (0.0179) hr-1, and 7.211 (2.862) liters/hr.kg, respectively.","Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247301/),[l] / [h·kg],7.211,261517,DB00262,Carmustine
,3247301,apparent rate constants,"The apparent rate constants for degradation of BCNU and CCNU were 0.09921 and 0.02853 hr-1 at 4 degrees C and 5.998 and 2.553 hr-1 at 37 degrees C, respectively.","Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247301/),1/[h],0.09921,261518,DB00262,Carmustine
,3247301,apparent rate constants,"The apparent rate constants for degradation of BCNU and CCNU were 0.09921 and 0.02853 hr-1 at 4 degrees C and 5.998 and 2.553 hr-1 at 37 degrees C, respectively.","Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247301/),1/[h],0.02853,261519,DB00262,Carmustine
,3247301,apparent rate constants,"The apparent rate constants for degradation of BCNU and CCNU were 0.09921 and 0.02853 hr-1 at 4 degrees C and 5.998 and 2.553 hr-1 at 37 degrees C, respectively.","Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247301/),1/[h],5.998,261520,DB00262,Carmustine
,3247301,apparent rate constants,"The apparent rate constants for degradation of BCNU and CCNU were 0.09921 and 0.02853 hr-1 at 4 degrees C and 5.998 and 2.553 hr-1 at 37 degrees C, respectively.","Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247301/),1/[h],2.553,261521,DB00262,Carmustine
,17264335,steady-state levels,"For up to 14 days, steady-state levels of O6-BG were 0.1 to 0.4 micromol/L, and levels for O6-benzyl-8-oxoguanine were 0.7 to 1.3 micromol/L.",Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17264335/),[μM] / [l],0.1 to 0.4,263465,DB00262,Carmustine
,17264335,steady-state levels,"For up to 14 days, steady-state levels of O6-BG were 0.1 to 0.4 micromol/L, and levels for O6-benzyl-8-oxoguanine were 0.7 to 1.3 micromol/L.",Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17264335/),[μM] / [l],0.7 to 1.3,263466,DB00262,Carmustine
,11960597,half-life,The half-life of BCNU in cells was approximately 40 min.,"In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11960597/),min,40,273574,DB00262,Carmustine
